Antheia
Menlo Park · Founded 2015
About Antheia
Antheia specializes in producing biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs) for essential medicines using synthetic biology. By engineering yeast to reconstruct complex biosynthetic pathways, the company converts simple sugars into pharmaceutical compounds through fermentation. This approach aims to reduce reliance on traditional agricultural sources and chemical synthesis, offering a more controlled and consistent supply chain. Antheia's product pipeline includes compounds for therapeutic areas such as neurology, oncology, and gastroenterology. The company supports pharmaceutical partners from development through regulatory submission to facilitate the adoption of biomanufactured ingredients.
Company Facts
- Founded: 2015
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $244.1M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2026)
- Website: http://www.antheia.bio
- Phone: 650-353-5191
Industries & Categories
Biotechnology, Health Care, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/antheia-52554 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.